logo-loader
viewXPhyto Therapeutics Corp.

Full interview: Xphyto Therapeutics acquires Vektor Pharma as company looks for rapid growth

Xphyto Therapeutics (CSE: XPHY) CEO Hugh Rogers sat down with Steve Darling from Proactive Vancouver with details about a key acquisition the company has made buying Vektor Pharma. They are a small German narcotics company. 

Rogers telling Proactive why this deal will accelerate the company’s plans for medical cannabis in Germany. Rogers also shared details about the thin film delivery system they have also acquired. 

Quick facts: XPhyto Therapeutics Corp.

Price: 2.2 CAD

CSE:XPHY
Market: CSE
Market Cap: $107.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

XPhyto kicks off exclusive partnership with brewing institute Weihenstephan

X-Phyto Therapeutics (CSE: XPHY-FSE:4XT) CEO Hugh Rogers sat down with Steve Darling from Proactive Vancouver to discuss a deal with the Technical University of Munich and the School of Life Sciences Weihenstephan. Rogers telling Proactive how the deal with work and the CEO also touched on...

4 days, 23 hours ago

2 min read